# NCT04680052 | Phase 3 | Relapsed/Refractory Follicular Lymphoma or Marginal Zone Lymphoma

Double-blind, Placebo-controlled, randomized, multicenter study evaluating Tafasitamab in combination with Lenalidomide and Rituximab versus Placebo plus Lenalidomide and Rituximab




## Primary end point

- PFS in FL population

## Secondary end points

- PFS and MRD-negativity rate in FL and MZL population
- OS, PET-CR, best ORR, DoR, QoL in overall and FL population
- Safety

## Select inclusion criteria

- Age ≥18
- Histologically confirmed Grade 1-3a FL, or nodal, splenic or extra nodel MZL
- ECOG PS 0-2
- Previously treated with at least 1 systemic anti-CD20 immunotherapy or chemo-immunotherapy
- Documented relapsed, refractory or PD after treatment with systemic therapy
- Ability and willingness to receive prophylaxis/treatment of thromboembolic events

## Select exclusion criteria

- Histology other than FL or MZL, or clinical evidence of transformed lymphoma
- Prior non-hematologic malignancy
- CNS lymphoma involvement
- Congestive heart failure
- Active systemic infection
- Prior use of Lenalidomide plus Rituximab
- Systemic anti-lymphoma/investigational therapy within 28 days prior cycle 1

**The efficacy and safety of the investigational compound discussed[a] have not been established. There is no guarantee that this compound[a] will become commercially available for the use(s) under investigation.**

For more information, visit IncyteClinicalTrials.com, contact us at +800 00027423 or by email at clintrials@incyte.com, or click on the QR code on the right to visit the trial on clinicaltrials.gov

**For reporting adverse events, contact eumedinfo@incyte.com or +49 8007239013**

[a] Tafasitamab

CNS: Central Nervous System; CR: Complete Response; DoR: Duration of response; ECOG PS: Eastern Cooperative Oncology Group Performance Status; FL: Follicular Lymphoma; IV: Intraveneous; MRD: Minimal Residual Disease; MZL: Marginal Zone Lymphoma; ORR: Overall Response Rate; OS: Overall Survival; PD: Progressive Disease; PET: Positron Emission Tomography; PFS: Progression-free Survival; PO: Peroral; Prim. Compl.: Primary Completion; QoL: Quality of Life; R/R: Refractory/Relapsed; https://clinicaltrials.gov/ct2/show/NCT04680052, Accessed 25 March,2021

DE/TAFACD19/NP/21/0012; 26 March 2021